In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what the pharmacist's role in MS supplement safety.
Amid the evolving landscape of MS treatments, there is an increasing emphasis on strategic approaches to early intervention and switching therapies.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Julie Kidd, PhD, MPH, BCPS, the director of clinical services at Blue Ridge Neurology, presenting on Supplements in Multiple Sclerosis, discussed what works and what doesn't in MS supplements.
ENHANCE trial data show ublituximab-xiiy can start with a single bioequivalent infusion, easing multiple sclerosis treatment initiation.
Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.
Dermatology care for skin of color can be improved by understanding inflammation-driven hyperpigmentation, safer treatments, and addressing education gaps that delay diagnosis and worsen outcomes.
Phase 3 UTOPIA trial shows UGN-103 intravesical mitomycin after TURBT achieves 78% complete response with favorable safety.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic, presenting on management of High-risk multiple sclerosis patients, discussed what the pharmacist's role is in managing high-risk MS patients.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic presenting on management of High-risk multiple sclerosis patients, discussed safety, treatment, and emerging strategies.
ASCO pooled phase 3 data show that pirtobrutinib in treatment‑naive CLL/SLL delivers 93% responses, durable control, and low cardiac risk.
Erin Zacholski, PharmD, BCOP, discusses the critical role of biomarker testing, immune checkpoint inhibitor selection, and pharmacist-led patient counseling in recurrent and metastatic endometrial cancer management.
New household data show recent COVID-19 shots cut at-home spread by 43%, strengthening pharmacist counseling on staying up to date.
Tim Casey addresses what this means for health care providers and pharmacists, and why this may represent a rare window for meaningful, bipartisan reform.
Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.
Craig Beavers highlights 3 major developments in cardiovascular and cardiometabolic medicine that pharmacists should have on their radar.
Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.
As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.
Bundibugyo Ebola spreads in DRC and Uganda as the WHO declares a public health emergency of international concern; learn the case counts, travel alerts, and pharmacist readiness steps.
Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.
Clinical pharmacists may play an increasingly important role in longitudinal metabolic care, medication optimization, patient education, and multidisciplinary peptide management.
Spencer Durham, PharmD, FCCP, BCPS, BCIDP, discusses why hepatitis B remains an active public health threat.
The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.
A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.
Community pharmacists emerged as the critical clinical link in the modern patient care continuum
This week's episode covers the White House's expansion of the TrumpRx.gov platform, the pharmacist's critical role in closing adult hepatitis B vaccination gaps, and new FDA approvals in immunology, oncology, and cardiovascular care.
Natalie Bellini, DNP, FNP-BC, BC-ADM, breaks down how updated ADA guidelines have broadened eligibility for continuous glucose monitors, automated insulin delivery systems, and continuous ketone monitoring.
Real-world data reveal that moderate to severe depression is linked to poor control and adherence, and women are more likely to be impacted.
If approved for this indication, finerenone would become the first nonsteroidal mineralocorticoid receptor antagonist indicated for adults with type 1 diabetes and CKD.
On World Schizophrenia Day, a psychiatric pharmacist details how EHR fragmentation drives medication errors in schizophrenia care, and why provider recognition is essential to fixing it.
Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.
